- Home
- AQMS vs KPRX Comparison
AQMS vs KPRX Comparison
Compare AQMS & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AQMS
- KPRX
- Stock Information
- Founded
- AQMS 2014
- KPRX 1998
- Country
- AQMS United States
- KPRX United States
- Employees
- AQMS N/A
- KPRX N/A
- Industry
- AQMS Metal Fabrications
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- AQMS Industrials
- KPRX Health Care
- Exchange
- AQMS Nasdaq
- KPRX Nasdaq
- Market Cap
- AQMS 10.3M
- KPRX 9.2M
- IPO Year
- AQMS 2015
- KPRX N/A
- Fundamental
- Price
- AQMS $5.93
- KPRX $2.75
- Analyst Decision
- AQMS Buy
- KPRX Strong Buy
- Analyst Count
- AQMS 1
- KPRX 1
- Target Price
- AQMS $30.00
- KPRX $10.00
- AVG Volume (30 Days)
- AQMS 2.6M
- KPRX 35.6K
- Earning Date
- AQMS 11-13-2025
- KPRX 11-07-2025
- Dividend Yield
- AQMS N/A
- KPRX N/A
- EPS Growth
- AQMS N/A
- KPRX N/A
- EPS
- AQMS N/A
- KPRX N/A
- Revenue
- AQMS N/A
- KPRX N/A
- Revenue This Year
- AQMS N/A
- KPRX N/A
- Revenue Next Year
- AQMS $550.00
- KPRX N/A
- P/E Ratio
- AQMS N/A
- KPRX N/A
- Revenue Growth
- AQMS N/A
- KPRX N/A
- 52 Week Low
- AQMS $3.37
- KPRX $2.25
- 52 Week High
- AQMS $34.84
- KPRX $4.18
- Technical
- Relative Strength Index (RSI)
- AQMS 56.15
- KPRX 55.26
- Support Level
- AQMS $3.75
- KPRX $2.67
- Resistance Level
- AQMS $8.25
- KPRX $2.89
- Average True Range (ATR)
- AQMS 1.15
- KPRX 0.11
- MACD
- AQMS 0.06
- KPRX 0.02
- Stochastic Oscillator
- AQMS 47.86
- KPRX 70.26
About AQMS Aqua Metals Inc.
Aqua Metals Inc is engaged in the business of recycling Lead through a novel, proprietary and patent-pending process that it developed and named AquaRefining. The company's breakthrough, AquaRefining, delivers a product, at a higher yield, eliminates toxic waste, reduces permitting, and is less expensive to build than smelting. AquaRefining process will provide for the recycling of Lead acid batteries and the production of a pure grade Lead with a significantly lower cost of production, and with fewer environmental and regulatory issues, than conventional methods of Lead production.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.